Aurora Bio, Inc Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition; Analysis of PET images indicated uptake of AUR01 (124I-p5+14) i
Dec 08, 2019 - Business Wire
Aurora Bio, Inc www.Aurorabioinc.com today announced data for the company's novel PET radiotracer, AUR01, in development for systemic amyloidosis, was presented by Dr. Jonathan Wall, at ASH2019, in Orlando, FL.
Spencer Guthrie, Chief Executive Officer, stated, "We are very excited about the results presented today on 1st 18 patients scanned with the investigational radiotracer, AUR01. We were excited to detect multiple organs in AL, ATTR and ALECT2 patients, and particularly asymptomatic o...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.